Conmed Q4 sales rise 7.9%, beat analyst estimates

Overview

• Medical technology firm's Q4 revenue rose 7.9%, beating analyst expectations

• Adjusted EPS for Q4 beat analyst expectations

• Company's international revenue grew 17% yr/yr, boosting overall sales

Outlook

• Conmed expects full-year 2026 revenue between $1.345 bln and $1.375 bln

• Company sees 2026 adjusted EPS between $4.30 and $4.45

• Conmed anticipates 4.5% to 6% organic growth in 2026

Result Drivers

• INTERNATIONAL GROWTH - International revenue increased 17% yr/yr, significantly boosting overall sales

• OPERATIONAL INITIATIVES - CEO Patrick J. Beyer cited progress on operational initiatives as a factor in Q4 results

• KEY GROWTH DRIVERS - Focus on minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

• Wall Street's median 12-month price target for Conmed Corp is $51.00, about 28.9% above its January 27 closing price of $39.58

• The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 10 three months ago

Press Release: ID:nBw5D10jMa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.